Transition probability matrix for standard-of-care (plus placebo) during the first cycle
| SAQAF EOT classification | ||||
|---|---|---|---|---|
| No | Monthly | Weekly | Daily | |
| SAQAF baseline classification | ||||
| No | – | – | – | – |
| Monthly | 1/20 (5.0%) 95% CI (0.9% to 24%) | 17/20 (85.0%) 95% CI (64% to 95%) | 2/20 (10.0%) 95% CI (3.0% to 30%) | 0/20 (0%) 95% CI (0% to 16%) |
| Weekly | 8/193 (4.1%) 95% CI (2% to 8%) | 65/193 (33.7%) 95% CI (27% to 41%) | 112/193 (58.0%) 95% CI (51% to 65%) | 8/193 (4.1%) 95% CI (2% to 8%) |
| Daily | 2/68 (2.9%) 95% CI (0.8% to 10%) | 9/68 (13.2%) 95% CI (7% to 23%) | 33/68 (48.5%) 95% CI (37% to 60%) | 24/68 (35.3%) 95% CI (25% to 47%) |
The SAQAF Domain category standard-of-care patients started in are depicted on the vertical axis (100=no, 61–99=monthly, 31–60=weekly and 0–30=daily symptoms) and the category they finished the double-blind trial period in is depicted on the horizontal axis. For example, 68 standard-of-care patients began the study reporting ‘daily’ angina symptoms and 24 (35.3%), 33 (48.5%), 9 (13.2%) and 2 (2.9%) of these same patients reported having daily, weekly, monthly and no angina symptoms at the end of the trial.
EOT, end-of-treatment; SAQAF, Seattle Angina Questionnaire Angina Frequency.